Lantern Pharma Inc forecasts a loss of 49 cents per share

Summary

Lantern Pharma Inc forecasts a loss of 49 cents per share for the quarter ending March 31, 2025, with unchanged quarterly revenue. Analysts have a ‘Buy’ rating with a 12-month median target price of $25.00, significantly higher than the last closing price of $3.54. The average earnings forecast has remained stable over the past three months Reuters.

Impact Analysis

1. Business Overview Analysis

• Lantern Pharma Inc is likely involved in the pharmaceutical industry, focusing on drug development and related businesses.
• The market position shows challenges given the significant difference between the target price and current trading price, indicating potential investor skepticism or market undervaluation.
• Recent significant events include the predicted loss and unchanged revenue expectations, suggesting operational or market difficulties.

2. Financial Statement Analysis

• Income Statement: The predicted loss per share indicates a lack of profitability, signaling margin pressures or high operational costs.
• Balance Sheet & Cash Flow: Specific details are not provided, but the unchanged revenue hints at potential issues in asset utilization or market performance.
• Ratios: Without specific figures, profitability metrics such as ROE and ROA are likely negative or weak, reflecting the predicted losses. Liquidity and solvency ratios cannot be assessed directly but may be under strain given the financial forecast.

Overall, this financial forecast points to short-term financial struggles, perhaps due to R&D costs, market conditions, or competitive pressures. However, the analyst ‘Buy’ rating and the significant price target suggest confidence in long-term recovery or strategic turnaround opportunities.